Study of Posaconazole Prophylaxis in Patients Receiving Hematopoietic Stem Cell Allograft (allo-HSC) At High Risk of Invasive Fungal Infection (IFI)

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 8, 2024

Primary Completion Date

January 15, 2027

Study Completion Date

November 8, 2028

Conditions
Hematologic Malignancy
Interventions
DRUG

Posaconazole

"Per Os, on Day 0 of allo-CSH if the patient's condition permits, or after the last dose of immunosuppressor (post-transplant cyclophosphamide) (Day+5 or Day+6 depending on protocols).~On the first day of treatment: 300 mg in the morning (= 3 x 100 mg tablets) and 300 mg in the evening (= 3 x 100 mg tablets), then from day 2 of treatment: 300 mg per day (= 3 x 100 mg tablets) in a single dose"

Trial Locations (1)

44000

RECRUITING

CHU Nantes, Nantes

All Listed Sponsors
lead

Nantes University Hospital

OTHER